|
Jun 3
|
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering
|
|
Jun 2
|
Immunic to Participate in Investor, Scientific and Industry Conferences in June
|
|
May 29
|
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering
|
|
May 28
|
Immunic, Inc. Announces Proposed Public Offering
|
|
Apr 10
|
Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
|
|
Apr 9
|
Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
|
|
Mar 3
|
Immunic to Participate in Scientific and Investor Conferences in March
|
|
Feb 26
|
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
|
|
Feb 22
|
Immunic, Inc.'s (NASDAQ:IMUX) largest shareholders are retail investors who were rewarded as market cap surged US$24m last week
|
|
Feb 20
|
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
|
|
Oct 9
|
Immunic Inc (IMUX) Q2 2024 Earnings Call Highlights: Promising Clinical Data and Financial ...
|
|
Jul 24
|
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec
|
|
Jul 9
|
Immunic Appoints Jason Tardio as Chief Operating Officer and President
|
|
May 9
|
Immunic, Inc. (NASDAQ:IMUX) Q1 2024 Earnings Call Transcript
|
|
May 9
|
We Think Immunic (NASDAQ:IMUX) Needs To Drive Business Growth Carefully
|
|
May 8
|
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
May 1
|
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
|
|
May 1
|
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
|
|
Apr 30
|
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
|
|
Apr 29
|
Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role
|